<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118209</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-50303</org_study_id>
    <secondary_id>CDR0000433265</secondary_id>
    <secondary_id>NCI-2009-00480</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>U10CA180821</secondary_id>
    <nct_id>NCT00118209</nct_id>
    <nct_alias>NCT00234351</nct_alias>
  </id_info>
  <brief_title>Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies rituximab when given together with two different
      combination chemotherapy regimens to compare how well they work in treating patients with
      diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, may
      block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy
      work in different ways to stop the growth of cancer cells, either by killing the cells, by
      stopping them from dividing, or by stopping them from spreading. Giving rituximab together
      with combination chemotherapy may kill more cancer cells. It is not yet known which
      combination chemotherapy regimen is more effective when given with rituximab in treating
      diffuse large B-cell non-Hodgkin's lymphoma.

      PURPOSE: This randomized phase III trial is studying rituximab when given together with two
      different combination chemotherapy regimens to compare how well they work in treating
      patients with diffuse large B-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the event-free survival of rituximab, cyclophosphamide, doxorubicin
      hydrochloride, vincristine sulfate, prednisone (R-CHOP) versus dose-adjusted (DA-) etoposide,
      prednisone, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, and rituximab
      (EPOCH-R) chemotherapy in untreated cluster of differentiation (CD)20 positive (+) diffuse
      large B-cell lymphomas.

      II. To develop a molecular predictor of outcome of R-CHOP and DA-EPOCH-R chemotherapy using
      molecular profiling.

      SECONDARY OBJECTIVES:

      I. To compare the response rates, overall survival and toxicity of R-CHOP versus DA-EPOCH-R.

      II. To define the pharmacogenomics of untreated diffuse large B-cell lymphoma (DLBCL) and
      correlate clinical parameters (toxicity, response, survival outcomes and laboratory results)
      with molecular profiling.

      III. To assess the use of molecular profiling for pathological diagnosis. IV. To identify new
      therapeutic targets using molecular profiling. V. To perform a comprehensive analysis of
      somatic alterations to the tumor genome and to understand which genomic alterations are
      somatically acquired by the tumor and which are encoded in the germ line of the patient.

      VI. To identify biomarkers of response to chemotherapy by fludeoxyglucose F 18 (FDG)-positron
      emission tomography (PET)/computed tomography (CT) imaging that are predictive of
      histopathologic remissions and survival in patients with stage I (mediastinal), II, III, or
      IV untreated DLBCL.

      VII. To evaluate the use of semiquantitative measurements of FDG uptake in defining
      FDG-PET/CT based biomarkers of response to chemotherapy in patients with DLBCL.

      VIII. To determine whether FDG-PET/CT measurements of tumor response after the second cycle
      of chemotherapy can predict clinical response.

      IX. To establish a standardized protocol for FDG-PET/CT image acquisition. X. To determine
      additional FDG-PET/CT parameters (e.g., the ratio of tumor maximum standard uptake value
      [SUVmax] to liver SUVmean; SUVs corrected for body surface area and lean body mass; nuclear
      medicine physician's assessment) and evaluate their utility in refining FDG-PET/CT based
      biomarkers of response to therapy.

      XI. To evaluate inter-institutional reproducibility of FDG-PET/CT measurements for this
      indication.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2005</start_date>
  <completion_date type="Actual">October 17, 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival Rate at 2 and 5 Years</measure>
    <time_frame>Up to 5 years post-registration</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse&gt;
â‰¥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders.&gt;
Appearance of any new lesion during or after completion of therapy.&gt;
PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven.&gt;
The PFS rate (percentage of participants who are alive and progression-free) at 2 and 5 years Kaplan Meier estimates and 95% Confidence Intervals are reported below.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 5 years post-registration</time_frame>
    <description>The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate at 2 and 5 Years</measure>
    <time_frame>Up to 5 years post-registration</time_frame>
    <description>Overall survival is defined as the time from randomization to death due to any cause. The overall survival (OS) rate (percentage of participants who are still alive) at 2 and 5 years Kaplan Meier estimates and 95% confidence intervals are reported below.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Whether the Gene Expression Signatures That Were Previously Associated With Survival Following CHOP Therapy Are Associated With Survival in Either of the Treatment Arms of the Prospective Trial</measure>
    <time_frame>Up to 5 years post-registration</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">524</enrollment>
  <condition>Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A - R-CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive the following treatment:
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy
Cyclophosphamide 750 mg/m^2 IV on Day 1
Doxorubicin 50 mg/m^2 IV on Day 1
Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1
Prednisone 40 mg/m^2/day PO on Days 1-5
filgrastim or pegfilgrastim as defined in the protocol
Required ancillary medications is administered during all cycles as defined in the protocol.
Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - DA-EPOCH-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive the following treatment:
Cycle 1 Doses:
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy
Doxorubicin 10 mg/m^2/day CIVI on Days 1-4
Etoposide 50 mg/m^2/day CIVI on Days 1-4
Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours)
Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions)
Prednisone 60 mg/m^2 PO BID on Days 1-5
Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC &gt; 5000 after the nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not being monitored, during every cycle.
Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle.
Required ancillary medications are administered during all cycles as defined in the protocol.
Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>IV</description>
    <arm_group_label>Arm A - R-CHOP</arm_group_label>
    <arm_group_label>Arm B - DA-EPOCH-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>IV</description>
    <arm_group_label>Arm A - R-CHOP</arm_group_label>
    <arm_group_label>Arm B - DA-EPOCH-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>IV or CIVI</description>
    <arm_group_label>Arm A - R-CHOP</arm_group_label>
    <arm_group_label>Arm B - DA-EPOCH-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
    <description>IV or CIVI</description>
    <arm_group_label>Arm A - R-CHOP</arm_group_label>
    <arm_group_label>Arm B - DA-EPOCH-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm A - R-CHOP</arm_group_label>
    <arm_group_label>Arm B - DA-EPOCH-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>CIVI</description>
    <arm_group_label>Arm B - DA-EPOCH-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>IV</description>
    <arm_group_label>Arm A - R-CHOP</arm_group_label>
    <arm_group_label>Arm B - DA-EPOCH-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>IV</description>
    <arm_group_label>Arm A - R-CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Histologically documented de novo CD20+ DLBCL with stage II, III or IV disease.

               -  Stage I primary mediastinal (thymic) DLBCL is also eligible.

               -  Patients with an underlying low-grade lymphoma, such as a transformed lymphoma or
                  low-grade lymphoma in the bone marrow, are not eligible.

               -  Diagnosis should be based on an adequate tissue sample, including open biopsy or
                  core needle biopsy.

               -  Needle aspiration for primary diagnosis is unacceptable.

               -  Patients must have one of the following WHO classification subtypes:

                    -  Diffuse large B-cell lymphoma (includes morphological variants:
                       centroblastic, immunoblastic, T-cell/histiocyte rich, and anaplastic)

                    -  Mediastinal (thymic) large B-cell lymphoma

                    -  Intravascular large B-cell lymphoma

               -  Note: Failure to submit a pathology block within 60 days of patient registration
                  will be considered a major protocol violation.

                    -  Fresh (frozen) tumor biopsy must be available or attempted. A frozen tumor
                       biopsy equivalent to a minimum of four at least 16 gauge needle cores is an
                       important component of this study.

                    -  Patients without adequate frozen material should have a biopsy performed to
                       obtain material.

                    -  If a biopsy is performed and does not yield adequate material, the patient
                       is still eligible for the study. If a biopsy cannot be done safely, the
                       patient may still be eligible for the study if permission is granted.

               -  Note: This study does not allow concurrent radiation unless a patient has a
                  documented CNS treatment failure with no systemic failure.

          2. No prior cytotoxic chemotherapy or rituximab. Patients may be entered if they have
             received prior limited field radiation therapy or a short course of glucocorticoids (&lt;
             10 days) for an urgent local disease complication at diagnosis (e.g., cord
             compression, SVC syndrome). Patients who have received chemotherapy for prior
             malignancies are not eligible.

          3. Age â‰¥ 18 years

          4. ECOG Performance Status 0-2

          5. No active ischemic heart disease or congestive heart failure. If there is suspicion of
             cardiac disease, a cardiac ejection fraction must show LVEF &gt; 45%, but the study is
             not required

          6. No known lymphomatous involvement of the CNS. A lumbar puncture prior to study is not
             required in the absence of neurological symptoms

          7. No known HIV disease. Patients with a history of intravenous drug abuse or any other
             behavior associated with an increased risk of HIV infection should be tested for
             exposure to the HIV virus. Patients who test positive or who are known to be infected
             are not eligible.

          8. Non pregnant and non-nursing. Treatment would expose an unborn child to significant
             risks. Women and men of reproductive potential should agree to use an effective form
             of contraception.

          9. Patients with active medical processes (e.g., uncontrolled bacterial or viral
             infection, bleeding) not related to their lymphoma should be excluded.

         10. Required Initial Laboratory Values (unless non-Hodgkin lymphoma):

               -  ANC â‰¥ 1000/Î¼L

               -  Platelets â‰¥ 100,000/Î¼L

               -  Creatinineâ‰¤ 1.5 mg/dL or creatinine clearance â‰¥ 50 cc/min

               -  Total Bilirubin â‰¤ 2 mg/dL (unless a history of Gilbert's Disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wyndham H. Wilson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew D. Zelenetz, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Camino Medical Group - Treatment Center</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Helena Hospital</name>
      <address>
        <city>Saint Helena</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-7243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creticos Cancer Center at Advocate Illinois Masonic Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alvin and Lois Lapidus Cancer Institute at Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Naval Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIH - Warren Grant Magnuson Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute at Providence Hospital - Southfield Campus</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Hospital Northeast-Northwest</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology - Hematology, PA - Hooksett</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <zip>03106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles R. Wood Cancer Center at Glens Falls Hospital</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <zip>12801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Weill Cornell Cancer Center at Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Cancer Center at Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233-3549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iredell Memorial Hospital</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Cancer Center at Altru Hospital</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center at Mercy Medical Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute at Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Easton Regional Cancer Center at Easton Hospital</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Hazleton Cancer Center</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224-1791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountainview Medical</name>
      <address>
        <city>Berlin</city>
        <state>Vermont</state>
        <zip>05602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center - Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Babb Randolph Cancer Center at West Virginia University Hospitals</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Lakeland Center</name>
      <address>
        <city>Minocqua</city>
        <state>Wisconsin</state>
        <zip>54548</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ministry Medical Group at Saint Mary's Hospital</name>
      <address>
        <city>Rhinelander</city>
        <state>Wisconsin</state>
        <zip>54501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Indianhead Center</name>
      <address>
        <city>Rice Lake</city>
        <state>Wisconsin</state>
        <zip>54868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic at Saint Michael's Hospital</name>
      <address>
        <city>Stevens Point</city>
        <state>Wisconsin</state>
        <zip>54481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Hospital Cancer Center</name>
      <address>
        <city>Stevens Point</city>
        <state>Wisconsin</state>
        <zip>54481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Weston Center</name>
      <address>
        <city>Weston</city>
        <state>Wisconsin</state>
        <zip>54476</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <results_first_submitted>April 6, 2020</results_first_submitted>
  <results_first_submitted_qc>April 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2020</results_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT00118209/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A - R-CHOP</title>
          <description>Patients receive the following treatment: &gt;
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy &gt;
Cyclophosphamide 750 mg/m^2 IV on Day 1 &gt;
Doxorubicin 50 mg/m^2 IV on Day 1 &gt;
Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1 &gt;
Prednisone 40 mg/m^2/day PO on Days 1-5 &gt;
filgrastim or pegfilgrastim as defined in the protocol &gt; Required ancillary medications is administered during all cycles as defined in the protocol. &gt; Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.</description>
        </group>
        <group group_id="P2">
          <title>Arm B - DA-EPOCH-R</title>
          <description>Patients receive the following treatment: &gt; Cycle 1 Doses: &gt;
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy &gt;
Doxorubicin 10 mg/m^2/day CIVI on Days 1-4 &gt;
Etoposide 50 mg/m^2/day CIVI on Days 1-4 &gt;
Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours) &gt;
Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions) &gt;
Prednisone 60 mg/m^2 PO BID on Days 1-5 &gt;
Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC &gt; 5000 after the &gt; nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not &gt; being monitored, during every cycle. &gt; Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. &gt; Required ancillary medications are administered during all cycles as defined in the protocol. &gt; Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="262"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable for Primary Endpoint</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable for Safety Analysis</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
                <participants group_id="P2" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who completed the study in the Participant Flow are included in this analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A - R-CHOP</title>
          <description>Patients receive the following treatment: &gt;
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy &gt;
Cyclophosphamide 750 mg/m^2 IV on Day 1 &gt;
Doxorubicin 50 mg/m^2 IV on Day 1 &gt;
Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1 &gt;
Prednisone 40 mg/m^2/day PO on Days 1-5 &gt;
filgrastim or pegfilgrastim as defined in the protocol &gt; Required ancillary medications is administered during all cycles as defined in the protocol. &gt; Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.</description>
        </group>
        <group group_id="B2">
          <title>Arm B - DA-EPOCH-R</title>
          <description>Patients receive the following treatment: &gt; Cycle 1 Doses: &gt;
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy &gt;
Doxorubicin 10 mg/m^2/day CIVI on Days 1-4 &gt;
Etoposide 50 mg/m^2/day CIVI on Days 1-4 &gt;
Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours) &gt;
Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions) &gt;
Prednisone 60 mg/m^2 PO BID on Days 1-5 &gt;
Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC &gt; 5000 after the &gt; nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not &gt; being monitored, during every cycle. &gt; Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. &gt; Required ancillary medications are administered during all cycles as defined in the protocol. &gt; Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="250"/>
            <count group_id="B2" value="241"/>
            <count group_id="B3" value="491"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Number analyzed in row differs from overall due to missing data.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="247"/>
                    <count group_id="B2" value="239"/>
                    <count group_id="B3" value="486"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" lower_limit="18.0" upper_limit="86.0"/>
                    <measurement group_id="B2" value="58.0" lower_limit="19.0" upper_limit="84.0"/>
                    <measurement group_id="B3" value="58.0" lower_limit="18.0" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Number analyzed in row differs from overall due to missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="249"/>
                    <count group_id="B2" value="241"/>
                    <count group_id="B3" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                    <count group_id="B2" value="241"/>
                    <count group_id="B3" value="491"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="434"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                    <count group_id="B2" value="241"/>
                    <count group_id="B3" value="491"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="385"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>Eastern Cooperative Oncology Group PS Scale: 0)Fully active, able to carry on all pre-disease performance without restriction; 1)Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2)Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3)Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4)Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.</description>
          <population>The number analyzed in row differs from overall due to missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="249"/>
                    <count group_id="B2" value="241"/>
                    <count group_id="B3" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival Rate at 2 and 5 Years</title>
        <description>Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse &gt;
â‰¥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders. &gt;
Appearance of any new lesion during or after completion of therapy. &gt;
PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven. &gt;
The PFS rate (percentage of participants who are alive and progression-free) at 2 and 5 years Kaplan Meier estimates and 95% Confidence Intervals are reported below.</description>
        <time_frame>Up to 5 years post-registration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm B - DA-EPOCH-R</title>
            <description>Patients receive the following treatment: &gt; Cycle 1 Doses: &gt;
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy &gt;
Doxorubicin 10 mg/m^2/day CIVI on Days 1-4 &gt;
Etoposide 50 mg/m^2/day CIVI on Days 1-4 &gt;
Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours) &gt;
Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions) &gt;
Prednisone 60 mg/m^2 PO BID on Days 1-5 &gt;
Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC &gt; 5000 after the &gt; nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not &gt; being monitored, during every cycle. &gt; Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. &gt; Required ancillary medications are administered during all cycles as defined in the protocol. &gt; Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Arm A - R-CHOP</title>
            <description>Patients receive the following treatment: &gt;
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy &gt;
Cyclophosphamide 750 mg/m^2 IV on Day 1 &gt;
Doxorubicin 50 mg/m^2 IV on Day 1 &gt;
Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1 &gt;
Prednisone 40 mg/m^2/day PO on Days 1-5 &gt;
filgrastim or pegfilgrastim as defined in the protocol &gt; Required ancillary medications is administered during all cycles as defined in the protocol. &gt; Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival Rate at 2 and 5 Years</title>
          <description>Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse &gt;
â‰¥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders. &gt;
Appearance of any new lesion during or after completion of therapy. &gt;
PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven. &gt;
The PFS rate (percentage of participants who are alive and progression-free) at 2 and 5 years Kaplan Meier estimates and 95% Confidence Intervals are reported below.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-year PFS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="73.8" upper_limit="84.2"/>
                    <measurement group_id="O2" value="75.5" lower_limit="70.2" upper_limit="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-year PFS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="62.1" upper_limit="74.5"/>
                    <measurement group_id="O2" value="66.0" lower_limit="60.2" upper_limit="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6519</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response)</description>
        <time_frame>Up to 5 years post-registration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm B - DA-EPOCH-R</title>
            <description>Patients receive the following treatment: &gt; Cycle 1 Doses: &gt;
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy &gt;
Doxorubicin 10 mg/m^2/day CIVI on Days 1-4 &gt;
Etoposide 50 mg/m^2/day CIVI on Days 1-4 &gt;
Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours) &gt;
Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions) &gt;
Prednisone 60 mg/m^2 PO BID on Days 1-5 &gt;
Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC &gt; 5000 after the &gt; nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not &gt; being monitored, during every cycle. &gt; Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. &gt; Required ancillary medications are administered during all cycles as defined in the protocol. &gt; Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Arm A - R-CHOP</title>
            <description>Patients receive the following treatment: &gt;
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy &gt;
Cyclophosphamide 750 mg/m^2 IV on Day 1 &gt;
Doxorubicin 50 mg/m^2 IV on Day 1 &gt;
Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1 &gt;
Prednisone 40 mg/m^2/day PO on Days 1-5 &gt;
filgrastim or pegfilgrastim as defined in the protocol &gt; Required ancillary medications is administered during all cycles as defined in the protocol. &gt; Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                    <measurement group_id="O2" value="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Rate at 2 and 5 Years</title>
        <description>Overall survival is defined as the time from randomization to death due to any cause. The overall survival (OS) rate (percentage of participants who are still alive) at 2 and 5 years Kaplan Meier estimates and 95% confidence intervals are reported below.</description>
        <time_frame>Up to 5 years post-registration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm B - DA-EPOCH-R</title>
            <description>Patients receive the following treatment: &gt; Cycle 1 Doses: &gt;
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy &gt;
Doxorubicin 10 mg/m^2/day CIVI on Days 1-4 &gt;
Etoposide 50 mg/m^2/day CIVI on Days 1-4 &gt;
Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours) &gt;
Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions) &gt;
Prednisone 60 mg/m^2 PO BID on Days 1-5 &gt;
Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC &gt; 5000 after the &gt; nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not &gt; being monitored, during every cycle. &gt; Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. &gt; Required ancillary medications are administered during all cycles as defined in the protocol. &gt; Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.</description>
          </group>
          <group group_id="O2">
            <title>Arm A - R-CHOP</title>
            <description>Patients receive the following treatment: &gt;
Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy &gt;
Cyclophosphamide 750 mg/m^2 IV on Day 1 &gt;
Doxorubicin 50 mg/m^2 IV on Day 1 &gt;
Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1 &gt;
Prednisone 40 mg/m^2/day PO on Days 1-5 &gt;
filgrastim or pegfilgrastim as defined in the protocol &gt; Required ancillary medications is administered during all cycles as defined in the protocol. &gt; Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Rate at 2 and 5 Years</title>
          <description>Overall survival is defined as the time from randomization to death due to any cause. The overall survival (OS) rate (percentage of participants who are still alive) at 2 and 5 years Kaplan Meier estimates and 95% confidence intervals are reported below.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-year OS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" lower_limit="82.3" upper_limit="91.0"/>
                    <measurement group_id="O2" value="85.7" lower_limit="81.4" upper_limit="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-year OS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="72.2" upper_limit="83.2"/>
                    <measurement group_id="O2" value="78.5" lower_limit="73.4" upper_limit="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6414</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Whether the Gene Expression Signatures That Were Previously Associated With Survival Following CHOP Therapy Are Associated With Survival in Either of the Treatment Arms of the Prospective Trial</title>
        <time_frame>Up to 5 years post-registration</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years</time_frame>
      <desc>All participants are followed for survival (i.e. included in the All-cause mortality table). Participants who received at least one dose of treatment are evaluable for adverse events (i.e. included in the Serious AE and Other (Not Including Serious) AE tables).</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A - R-CHOP</title>
          <description>Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.</description>
        </group>
        <group group_id="E2">
          <title>Arm B - DA-EPOCH-R</title>
          <description>Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="243"/>
                <counts group_id="E2" events="64" subjects_affected="43" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="488" subjects_affected="193" subjects_at_risk="243"/>
                <counts group_id="E2" events="564" subjects_affected="201" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Spleen disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Extraocular muscle paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="243"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Anal mucositis (clin exam)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="128" subjects_affected="84" subjects_at_risk="243"/>
                <counts group_id="E2" events="119" subjects_affected="81" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Esophageal mucositis (clin exam)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Mucositis oral (clin exam)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" events="28" subjects_affected="23" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Mucositis oral (funct/sympt)</sub_title>
                <counts group_id="E1" events="31" subjects_affected="18" subjects_at_risk="243"/>
                <counts group_id="E2" events="55" subjects_affected="32" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="21" subjects_at_risk="243"/>
                <counts group_id="E2" events="25" subjects_affected="15" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="243"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="243"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="41" subjects_affected="27" subjects_at_risk="243"/>
                <counts group_id="E2" events="60" subjects_affected="41" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gait abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="243"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Immune system disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Anorectal infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bladder infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bladder infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bronchitis(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bronchitis(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Catheter related infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Colitis, infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Device related infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Esophageal infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Esophageal infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gingival infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gingival infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Infectious colitis(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nail infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Otitis externa(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Otitis media(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Paranasal sinus infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonia(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonia(unknown ANC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sepsis(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sepsis(unknown ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sinusitis(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sinusitis(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Skin infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Tooth infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Upper respiratory infectn(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary tract infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary tract infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vaginal infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Wound infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial throm time prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="18" subjects_affected="6" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="117" subjects_affected="72" subjects_at_risk="243"/>
                <counts group_id="E2" events="242" subjects_affected="105" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="114" subjects_affected="60" subjects_at_risk="243"/>
                <counts group_id="E2" events="231" subjects_affected="86" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="331" subjects_affected="179" subjects_at_risk="243"/>
                <counts group_id="E2" events="506" subjects_affected="190" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="182" subjects_affected="97" subjects_at_risk="243"/>
                <counts group_id="E2" events="479" subjects_affected="184" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum cholesterol increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="243"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="37" subjects_affected="20" subjects_at_risk="243"/>
                <counts group_id="E2" events="39" subjects_affected="25" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="243"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="28" subjects_affected="15" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum calcium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum magnesium decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum magnesium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="44" subjects_affected="29" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum potassium increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum sodium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="28" subjects_affected="17" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arachnoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="243"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="243"/>
                <counts group_id="E2" events="62" subjects_affected="36" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="186" subjects_affected="104" subjects_at_risk="243"/>
                <counts group_id="E2" events="322" subjects_affected="141" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Kidney pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Testicular hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pharyngeal mucositis (funct/sympt)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pharyngeal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" events="19" subjects_affected="8" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Body odor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hand-and-foot syndrome/reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="243"/>
                <counts group_id="E2" events="57" subjects_affected="44" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="126" subjects_affected="80" subjects_at_risk="243"/>
                <counts group_id="E2" events="199" subjects_affected="116" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lymphatic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Asystole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="243"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="243"/>
                <counts group_id="E2" events="45" subjects_affected="35" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="243"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Duodenal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Jejunal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Mucositis oral (clin exam)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Mucositis oral (funct/sympt)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="243"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Small intestinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="243"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Visceral edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Immune system disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Abdominal infection(unknown ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Anorectal infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bladder infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bladder infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bronchitis(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Catheter related infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Catheter related infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Colitis, infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Esophageal infection(unknown ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gingival infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Infectious colitis(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Infectious colitis(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lip infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lymph gland infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Mucosal infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pancreas infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Peritoneal infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonia(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonia(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonia(unknown ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sepsis(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sepsis(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sepsis(unknown ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Skin infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Tooth infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Upper respiratory infectn(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary tract infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary tract infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vaginal infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vaginal infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Wound infection(gr 0/1/2 ANC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Wound infection(gr 3/4 ANC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Intraop. inj. - Spinal cord</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Venous injury - Viscera</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial throm time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="58" subjects_affected="42" subjects_at_risk="243"/>
                <counts group_id="E2" events="106" subjects_affected="66" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="52" subjects_affected="34" subjects_at_risk="243"/>
                <counts group_id="E2" events="93" subjects_affected="51" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="109" subjects_affected="74" subjects_at_risk="243"/>
                <counts group_id="E2" events="169" subjects_affected="107" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="73" subjects_affected="53" subjects_at_risk="243"/>
                <counts group_id="E2" events="167" subjects_affected="107" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum cholesterol increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="243"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="243"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="243"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="243"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum calcium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum glucose decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum magnesium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum magnesium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="28" subjects_affected="23" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum potassium increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="243"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum sodium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Serum triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Muscle weakness right-sided</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Neck soft tissue necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Mini mental status examination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="243"/>
                <counts group_id="E2" events="108" subjects_affected="68" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Kidney pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urogenital disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="243"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pharyngeal mucositis (clin exam)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="243"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy Bartlett, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-5654</phone>
      <email>nbartlet@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

